Home
Storia in 2 fonti
Merck to buy Terns Pharmaceuticals for $6.7 billion to boost cancer pipeline
Merck is trying to bulk up its portfolio ahead of its best-selling cancer drug Keytruda losing patent protection in 2028.
- ·
ft.com
Merck nears $6bn biotech deal to boost cancer drug pipeline
Terns Pharma stock has jumped since promising clinical data on its bone and blood cancer treatment last year
- ·
cnbc.com
Merck to buy Terns Pharmaceuticals for $6.7 billion to boost cancer pipeline
Merck is trying to bulk up its portfolio ahead of its best-selling cancer drug Keytruda losing patent protection in 2028.